Ozempic Baby Boom: New Pregnancy Guidance Issued
Ozempic Baby Boom: New Pregnancy Guidance Issued
Ozempic Baby Boom: New Pregnancy Guidance Issued
Key points
اہم نکات
मुख्य बातें
- Doctors have issued their first-ever guidance on GLP-1 weight-loss drugs and pregnancy, after a wave of so-called 'Ozempic babies' left patients and doctors confused.
- The American College of Obstetricians and Gynecologists released the guidance in October, as NPR's Short Wave reported, because the drugs can restore ovulation in some women — especially those with polycystic ovary syndrome — and tirzepatide can make birth-control pills less reliable.
- The guidance says the drugs are not approved in pregnancy and should be stopped at least two months before a planned pregnancy.
- Doctors have issued their first-ever guidance on GLP-1 weight-loss drugs and pregnancy, after a wave of so-called 'Ozempic babies' left patients and doctors confused.
- The American College of Obstetricians and Gynecologists released the guidance in October, as NPR's Short Wave reported, because the drugs can restore ovulation in some women — especially those with polycystic ovary syndrome — and tirzepatide can make birth-control pills less reliable.
- The guidance says the drugs are not approved in pregnancy and should be stopped at least two months before a planned pregnancy.
- Doctors have issued their first-ever guidance on GLP-1 weight-loss drugs and pregnancy, after a wave of so-called 'Ozempic babies' left patients and doctors confused.
- The American College of Obstetricians and Gynecologists released the guidance in October, as NPR's Short Wave reported, because the drugs can restore ovulation in some women — especially those with polycystic ovary syndrome — and tirzepatide can make birth-control pills less reliable.
- The guidance says the drugs are not approved in pregnancy and should be stopped at least two months before a planned pregnancy.
Doctors have issued their first-ever guidance on GLP-1 weight-loss drugs and pregnancy, after a wave of so-called 'Ozempic babies' left patients and doctors confused. The American College of Obstetricians and Gynecologists released the guidance in October, as NPR's Short Wave reported, because the drugs can restore ovulation in some women — especially those with polycystic ovary syndrome — and tirzepatide can make birth-control pills less reliable. The guidance says the drugs are not approved in pregnancy and should be stopped at least two months before a planned pregnancy. A study of 3,572 pregnancies published November 3 found no large rise in birth defects from early exposure, but experts say the data are still too limited to prove safety.
Doctors have issued their first-ever guidance on GLP-1 weight-loss drugs and pregnancy, after a wave of so-called 'Ozempic babies' left patients and doctors confused. The American College of Obstetricians and Gynecologists released the guidance in October, as NPR's Short Wave reported, because the drugs can restore ovulation in some women — especially those with polycystic ovary syndrome — and tirzepatide can make birth-control pills less reliable. The guidance says the drugs are not approved in pregnancy and should be stopped at least two months before a planned pregnancy. A study of 3,572 pregnancies published November 3 found no large rise in birth defects from early exposure, but experts say the data are still too limited to prove safety.
Doctors have issued their first-ever guidance on GLP-1 weight-loss drugs and pregnancy, after a wave of so-called 'Ozempic babies' left patients and doctors confused. The American College of Obstetricians and Gynecologists released the guidance in October, as NPR's Short Wave reported, because the drugs can restore ovulation in some women — especially those with polycystic ovary syndrome — and tirzepatide can make birth-control pills less reliable. The guidance says the drugs are not approved in pregnancy and should be stopped at least two months before a planned pregnancy. A study of 3,572 pregnancies published November 3 found no large rise in birth defects from early exposure, but experts say the data are still too limited to prove safety.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।